MLM-CAR44.1 T-cell therapy (MolMed)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameMLM-CAR44.1 T-cell therapy (MolMed)
Drug Alias NameMLM-CAR44.1 T细胞疗法-MolMedAutologous CD44v6 CAR T-cell therapy
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCD44 antigen modulatorsT lymphocyte replacements
TargetsCD44 antigen
Therapy Area/IndicationsMultiple MyelomaLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaItaly
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMolmed Spa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAgc Biologics
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A